GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%
Full details of GSK's results for the second quarter of 2011 can be found in the
Issued: London, UK
Full details of GSK's results for the second quarter of 2011 can be found in the Investors section of GSK.com.
GlaxoSmithKline enquiries:
|
UK Media enquiries: |
David Mawdsley |
(020) 8047 5502 |
|
|
Stephen Rea |
(020) 8047 5502 |
|
|
Sarah Spencer |
(020) 8047 5502 |
|
Janet Morgan |
(020) 8047 5502 |
|
|
David Daley |
(020) 8047 5502 |
|
|
|
|
|
|
US Media enquiries: |
Nancy Pekarek |
(919) 483 2839 |
|
|
Mary Anne Rhyne |
(919) 483 2839 |
|
|
Kevin Colgan |
(919) 483 2839 |
|
|
Jennifer Armstrong |
(919) 483 2839 |
|
|
|
|
|
European Analyst/Investor enquiries: |
Sally Ferguson |
(020) 8047 5543 |
|
|
Gary Davies |
(020) 8047 5503 |
|
|
Ziba Shamsi |
(020) 8047 3289 |
|
|
|
|
|
US Analyst/ Investor enquiries: |
Tom Curry |
(215) 751 5419 |
|
Jeff McLaughlin |
(215) 751 7002 |
